Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. in vitro assays
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This week
  • This month
  • This Year
  • Older

In Vitro Assays Articles & Analysis

19 news found

Myelotracker joins Bertin’s Bioreagent portfolio

Myelotracker joins Bertin’s Bioreagent portfolio

We are proud to introduce Myelotracker®, a peptide-based probe. This unique technology specifically targets lactoferrin, a major protein stored in neutrophil granules, making it possible to visualize and study these immune cells with unmatched precision. Unlike many existing tools, Myelotracker does not activate neutrophils, preserving their natural physiological state and ensuring reliable ...

ByBertin Technologies


Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...

ByAdvanced Instruments


Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products

Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products

The scientists at Sirenas have run these samples through cutting edge and proprietary chemical extraction and analytics and tested each one in over 70 in-vitro biological assays relevant to human health. The result is the largest repository of information connecting the unchartered chemistry of marine organisms to applications in human health. ...

BySirenas


Structure-Based Search for Novel Antihypercholestrolemic Agents

Structure-Based Search for Novel Antihypercholestrolemic Agents

To that end, we will integ rate virtual (computer) screening methods and cell-based assays to identify lead compounds that can potentially be optimized to produce a cholesterol lowering drugs. Virtual screening, which requires the availability of atomic resolution 3D structures of the target protein, provides a cost effective way to screen million of compounds to identify just a ...

ByShifa Biomedical Corporation


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

The proof of concept has been established with 100% killing of malaria parasites in in-vitro assays, and greater than 90% killing of malaria parasites in mRNA-based immunization of non-human primates. ...

ByOcean Biomedical


Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo. ...

ByAffimed GmbH


Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclib’s inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib. ...

ByTraws Pharma


Pronalyse Unveils Therapeutic Enzyme Characterization Service for Your Drug Development

Pronalyse Unveils Therapeutic Enzyme Characterization Service for Your Drug Development

Creative Proteomics's comprehensive suite of protein analysis services brings together a variety of methods, including amino acid analysis, concentration/yield assays, cell potential and in vitro cell culture, glycosylation assays, post-translational modifications, etc. ...

ByCreative Proteomics


Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian designed genetically engineered IL2-free TILs (cytoTIL15™) to express a regulated form of membrane-bound IL15 for tunable long-term persistence, leading to enhanced persistence and efficacy in vitro and in PDX tumor models. Obsidian previously demonstrated cytoTIL15 exhibited enhanced potency and persistence over conventional TILs in vitro, and ...

ByObsidian Therapeutics, Inc.


Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Oral presentation highlights: Utilizing Araris' linker technology, an anti-Nectin-4 ADC was generated within 24 hours resulting in highly homogenous and pure ADCs with a DAR of ~ 2 and > 98% monomeric content. In In-vitro assays against target positive cell lines, the Araris ADC demonstrated low nM-range cytotoxicity similar to approved enfortrumab-vedotin ...

ByAraris Biotech AG


Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Oral presentation highlights: Utilizing Araris’ linker technology, an anti-Nectin-4 ADC was generated within 24 hours resulting in highly homogenous and pure ADCs with a DAR of ~ 2 and > 98% monomeric content. In In-vitro assays against target positive cell lines, the Araris ADC demonstrated low nM-range cytotoxicity similar to approved ...

ByAraris Biotech AG


Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

The translation of previously observed in vitro and in vivo persistence of cytoTIL15 TILs, in the absence of IL2, to superior in vivo anti-tumor efficacy in PDX models supports the potential for increased efficacy of cytoTIL15 therapy over conventional TIL therapy in solid tumor malignancies. ...

ByObsidian Therapeutics, Inc.


Altis Biosystems Announces New Research Funding Initiative

Altis Biosystems Announces New Research Funding Initiative

There is an intense need for more accurate screening methods during preclinical studies using in vitro assays that more closely mimic in vivo conditions. Currently, only 12% of drugs that begin phase 1 clinical trials move on to eventually receive FDA approval. ...

ByAltis Biosystems


Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. “We are excited to have reached this important milestone of submitting our first IND application to the FDA on our most advanced therapeutics program. ...

ByQualigen Therapeutics, Inc.


StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

Furthermore, Matrix Plus promoted mature hiPSC-CM electrophysiological function and enabled the in vitro visualization of reentrant arrhythmia responsible for fatal cardiac events in humans. Lastly, and importantly, Matrix Plus enabled high throughput cardiotoxicity screening using mature human cardiomyocytes with validation utilizing reference compounds recommended for the ...

ByStemBioSys, Inc.


Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico's co-ownership of the successfully developed programs under agreed payment. ...

ByInsilico Medicine


Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer`s Disease Therapy

Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer`s Disease Therapy

The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach. ...

ByOligomerix, Inc.


Accuracy of comet measurements in image analysis systems

Accuracy of comet measurements in image analysis systems

If you are scoring comets using image analysis, you will want to be confident that the results you are getting are accurate. Comet Assay IV from Perceptive Instruments has a unique scoring method that has been validated both in-house and by many of the world’s leading pharmaceutical organisations and CROs. As part of the JaCVAM initiative to validate the in vivo and in ...

ByInstem Group


EU project shows eating right does the body good

'So far the biological and protective activities of various flavonoids have been extensively studied in vitro, on cell-based assays,' explains researcher and leading author of the study, Dr Marie-Claire Toufektsian of Joseph Fourier University in Grenoble, France. ...

ByEuropean Commission, Directorate General for Research & Innovation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT